Browsing by Author "Maral, Senem"
Now showing items 1-5 of 5
-
Clinical characteristics and outcomes of COVID-19 in Turkish patients with hematological malignancies
Civriz Bozdağ, Sinem; Cengiz Seval, Güldane; Yönal Hindilerden, İpek; Hindilerden, Fehmi; Andıç, Neslihan; Baydar, Mustafa; Aydın Kanyar, Lale; Toprak, Selami Koçak; Göksoy, Hasan Sami; Balık Aydın, Berrin; Demirci, Ufuk; Can, Ferda; Özkocaman, Vildan; Gündüz, Eren; Güven, Zeynep Tuğba; Özkurt, Zübeyde Nur; Demircioğlu, Sinan; Beksaç, Meral; İnce, İdris; Yılmaz, Umut; Eroğlu Küçükdiler, Hilal; Abishov, Elgün; Yavuz, Boran; Ataş, Ünal; Mutlu, Yaşa Gül; Baş, Volkan; Özkalemkaş, Fahir; Üsküdar Teke, Hava; Gürsoy, Vildan; Çelik, Serhat; Çiftçiler, Rafiye; Yağcı, Münci; Topçuoğlu, Pervin; Çeneli, Özcan; Abbasov, Hamza; Selim, Cem; Ar, Muhlis Cem; Yücel, Orhan Kemal; Sadri, Sevil; Albayrak, Canan; Demir, Ahmet Muzaffer; Güler, Nil; Keklik, Muzaffer; Terzi, Hatice; Doğan, Ali; Yegin, Zeynep Arzu; Kurt Yüksel, Meltem; Sadri, Soğol; Yavaşoğlu, İrfan; Beköz, Hüseyin Saffet; Aksu, Tekin; Maral, Senem; Erol, Veysel; Kaynar, Leylagül; İlhan, Osman; Bolaman, Ali Zahit; Sevindik, Ömür Gökmen; Akyay, Arzu; Özcan, Muhit; Gürman, Günhan; Ünal, Şule; Yavuz, Yasemin; Diz Küçükkaya, Reyhan; Özsan, Güner Hayri (NLM (Medline), 2022)Objective: Patients with solid malignancies are more vulnerable to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection than the healthy population. The outcome of SARS-CoV-2 infection in highly ... -
An interim analysis of the Turkish Myeloma Registry among patients who have received up to two lines of therapy
Sevindik, Ömür Gökmen; Özkurt, Zübeyde Nur; Boğa, Can; Kalayoğlu Beşışık, Sevgi; İpek, Yıldız; Gedük, Ayfer; Harmandalı, Aybüke; Salihoğlu, Ayşe; Haydaroğlu Şahin, Handan; Sönmez, Mehmet; Vural, Filiz; Akay, Olga Meltem; Kurt Yüksel, Meltem; Maral, Senem; Ekinci, Ömer; Kırkızlar, Hakkı Onur; Tekinalp, Atakan; Demir, Nazlı; Merter, Mustafa; Saydam, Güray; Alacacıoğlu, İnci; Yeğin, Zeynep Arzu; Kasar, Mutlu; Mastanzade, Metban; Özsan, Güner Hayri (CIG Media Group, 2021)Background To investigate the demographics and treatment details of the myeloma patients who were diagnosed and followed up in Turkey and received up to two lines of therapy. Methods Patients who were recorded on the ... -
An interim analysis of the Turkish myeloma registry among the patients who have received up to two lines of therapy
Sevindik, Ömür Gökmen; Özkurt, Zübeyde Nur; Boğa, Can; Kalayoğlu Beşışık, Sevgi; Yıldız, İpek; Gedük, Ayfer; Harmandali, Aybüke; Salihoğlu, Ayşe; Haydaroğlu Şahin, Handan; Sönmez, Mehmet; Vural, Filiz; Akay, Olga Meltem; Kurt Yüksel, Meltem; Maral, Senem; Ekinci, Ömer; Kırkızlar, Hakkı Onur; Tekinalp, Atakan; Demir, Nazlı; Merter, Mustafa; Saydam, Güray; Alacacıoğlu, İnci; Yeğin, Zeynep Arzu; Kaşar, Mutlu; Mastanzade, Metban; Özsan, Güner Hayri (American Society of Hematology, 2021)... -
A real-life Turkish experience of venetoclax treatment in high-risk myelodysplastic syndrome and acute myeloid leukemia
Gemici, Aliihsan; Özkalemkaş, Fahir; Doğu, Mehmet Hilmi; Tekinalp, Atakan; Alacacıoğlu, İnci; Güney, Tekin; İnce, İdris; Gedük, Ayfer; Akgün Çağlıyan, Gülsüm; Maral, Senem; Serin, İstemi; Gündüz, Eren; Karakuş, Volkan; Beköz, Hüseyin Saffet; Eren, Rafet; Pınar, İbrahim Ethem; Güneş, Ahmet Kürşad; Sargın, Fatma Deniz; Sevindik, Ömür Gökmen (CIG Media Group, 2021)Venetoclax is a selective B-cell lymphoma 2 (BCL2) inhibitor, which is approved to treat elderly patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). A total of 60 patients ... -
Survival outcomes of hypomethylating agents maintenance therapy in new diagnosed AML patients: Real experience data
Karakuş, Volkan; Maral, Senem; Kaya, Egemen; Gemici, Aliihsan; Dere, Yelda; Sevindik, Ömür Gökmen (Kare Publishing, 2022)OBJECTIVE: Acute myeloid leukemia (AML) is a hematological malignancy that frequently affects elderly population. With introducing the hypomethylating agents (HMAs) in elderly AML treatment, survival rates and quality of ...
